Lupin launches Betamethasone Dipropionate Ointment USP (Augmented)

Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin's Pithampur (Unit III) facility, India.

Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, is the generic equivalent of Diprolene® Ointment, 0.05%, of Merck Sharp and Dohme Corp. It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.

Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, (RLD: Diprolene®) had annual sales of approximately USD 21 million in the U.S. (IQVIA MAT January 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Read also: Lupin Receives International Sustainability Rating System (ISRS) Certification